Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 1b clinical trial for VK0214, a novel thyroid hormone receptor beta agonist, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The trial, which is randomized and double-blind, targets adult male patients with the adrenomyeloneuropathy form of X-ALD. Key objectives include evaluating VK0214's safety, tolerability over 28 days, and its efficacy in lowering plasma levels of very long-chain fatty acids. VK0214, having completed an earlier successful Phase 1 study, has shown promising safety and pharmacokinetics.
Viking Therapeutics (NASDAQ: VKTX) announced positive results from its Phase 1 clinical trial of VK0214, a thyroid receptor beta agonist targeting X-linked adrenoleukodystrophy (X-ALD). The study confirmed VK0214's safety and tolerability with no serious adverse events and a favorable pharmacokinetic profile. Notably, VK0214 significantly reduced low-density lipoprotein cholesterol (LDL-C), triglycerides, and apolipoprotein B, indicating potential therapeutic benefits. Viking plans to commence a Phase 1b study in X-ALD patients soon.
Viking Therapeutics (NASDAQ: VKTX), a biopharmaceutical company focused on therapies for metabolic disorders, will participate in two upcoming investor conferences. On June 17, 2021, Viking will engage in 1-on-1 meetings at the SVB Leerink CybeRx Series: Liver Disease Day. Following that, from June 21-23, 2021, they will host a panel discussion on June 23 at 12:00 p.m. Eastern during the Raymond James Human Health Innovations Conference. Viking is also developing innovative drugs like VK2809 for NASH and VK0214 for X-ALD, aiming to enhance patient outcomes.
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported its financial results for Q1 2021, revealing a net loss of $14.0 million, or $0.19 per share, compared to a $9.7 million loss in Q1 2020. The company continues its Phase 2b VOYAGE trial for VK2809 in NASH, with enrollment expected to complete in H2 2021. The cash balance stands at approximately $242 million, providing a strong runway for its clinical programs. Key advancements include ongoing trials for VK0214, aimed at treating X-ALD, with a Phase 1b study anticipated this summer.
Viking Therapeutics (NASDAQ: VKTX) announces it will release its Q1 2021 financial results after market close on April 28, 2021. A conference call to discuss these results and corporate updates will commence at 4:30 p.m. ET on the same day. Interested parties can participate via phone or listen online through the company's webcast. Viking is focused on developing therapies for metabolic and endocrine disorders, with key projects including VK2809 for NASH and VK0214 for X-ALD.
Viking Therapeutics announces that CEO Brian Lian, Ph.D., will present at the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. His presentation is scheduled for April 14 from 3:45 – 4:25 p.m. Eastern. The company focuses on developing innovative therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK0214 is also in a Phase 1 trial for X-linked adrenoleukodystrophy (X-ALD). For more information, visit vikingtherapeutics.com.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in three upcoming investor conferences. The first is the HC Wainwright Global Life Science Conference on March 9-10, 2021, where a corporate presentation will be available online. This is followed by the 33rd Annual Roth Conference on March 15-17 and the Oppenheimer's 31st Annual Healthcare Conference on March 16-18, with presentations and meetings scheduled. The company focuses on therapies for metabolic disorders, including its drugs VK2809 and VK0214, currently in clinical trials.
Viking Therapeutics (NASDAQ: VKTX) reported its fourth quarter and full-year 2020 financial results, revealing a net loss of $10.9 million for Q4, up from $7.5 million in Q4 2019. The total net loss for 2020 was $39.5 million, compared to $25.8 million in 2019. R&D expenses surged to $31.9 million, driven by clinical trial costs. The company maintains a strong balance sheet with $248.4 million in cash. Viking's ongoing VOYAGE trial for VK2809 and progress in the VK0214 program highlight its focus on metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) will report its financial results for Q4 and year-end 2020 after market close on February 17, 2021. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and corporate updates. Investors can participate by dialing (844) 850-0543 or (412) 317-5199, and a telephone replay will be available until February 24, 2021. Viking is focused on metabolic and endocrine disorder therapies, with ongoing clinical programs for VK2809 and VK0214.
On January 6, 2021, Viking Therapeutics (NASDAQ: VKTX) announced the promotion of Greg Zante to Chief Financial Officer and Marianne Mancini to Chief Operating Officer. Zante brings nearly 25 years of experience in financial management and previously served as Senior Vice President of Finance at Viking. Mancini has over 30 years of experience, focusing on clinical trials, and was previously Senior Vice President of Clinical Operations. These promotions reflect their significant contributions to the company, particularly in advancing therapies for metabolic disorders including non-alcoholic steatohepatitis (NASH).
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
